TrialBlood2025

Acalabrutinib treatment for older (aged ≥80 years) and/or frail patients with CLL: primary end point analysis of the CLL-Frail trial.

Florian Simon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.